← Back to Search

Teleophthalmology for Diabetic Retinopathy

N/A
Waitlist Available
Led By Yao Liu, MD, MS
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (data is retrospective to evaluate pre-intervention beginning november 2022) and 12, 24, and 36 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a program called I-SITE to see if it can help maintain higher rates of diabetic eye screening using teleophthalmology in city health systems with multiple payers.

Who is the study for?
This trial is for individuals with type 1 or type 2 diabetes who are part of an urban health system and have had diabetic eye screenings. Participants' medical records must include specific ICD-10 codes for diabetes and billing data for teleophthalmology services.
What is being tested?
The study tests the I-SITE program's effectiveness in maintaining high rates of diabetic eye screening through teleophthalmology, compared to usual care, within urban health systems that cater to multiple insurance payers.
What are the potential side effects?
Since this trial focuses on implementing a service delivery method rather than a drug, traditional side effects are not applicable. However, there may be indirect consequences related to accessibility, satisfaction or accuracy of the teleophthalmology service.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~data collected monthly (retrospectively beginning november 2022 and up to 36 months prospectively)
This trial's timeline: 3 weeks for screening, Varies for treatment, and data collected monthly (retrospectively beginning november 2022 and up to 36 months prospectively) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Diabetic Screening Rate
Secondary study objectives
Follow Up Rate For In-Person Eye Care Among Screen Positives
Monthly Teleophthalmology Use

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Usual Care Followed by I-SITE InterventionExperimental Treatment2 Interventions

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,234 Previous Clinical Trials
3,198,291 Total Patients Enrolled
5 Trials studying Diabetic Retinopathy
7,772 Patients Enrolled for Diabetic Retinopathy
National Eye Institute (NEI)NIH
556 Previous Clinical Trials
1,405,470 Total Patients Enrolled
50 Trials studying Diabetic Retinopathy
40,845 Patients Enrolled for Diabetic Retinopathy
Yao Liu, MD, MSPrincipal InvestigatorUW School of Medicine and Public Health
2 Previous Clinical Trials
1,536 Total Patients Enrolled
2 Trials studying Diabetic Retinopathy
1,536 Patients Enrolled for Diabetic Retinopathy
~1333 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top